Polyamine metabolism: a potential therapeutic target in trypanosomes.
alpha-Difluoromethylornithine (RMI 71,782), a specific irreversible inhibitor of the first step in polyamine biosynthesis, that is, the formation of putrescine from ornithine by ornithine decarboxylase, cures mice infected with a virulent, rodent-passaged strain of Trypanosoma brucei brucei. This parasite is closely related to the trypanosomes that cause human sleeping sickness. The drug, which is remarkably nontoxic, was effective when administered in drinking water or by intubation. The ability of the compound to inhibit ornithine decarboxylase in vitro was demonstrated by the reduced amounts of putrescine synthesized from tritiated ornithine in Trypanosoma brucei suspensions. These observations direct attention to polyamine metabolism as a target for chemotherapy of parasitic diseases.
D000818:Animals; D000518:Eflornithine; D051379:Mice; D009952:Ornithine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D065108:Ornithine Decarboxylase Inhibitors; D011073:Polyamines / Q000378:metabolism*; D014344:Trypanocidal Agents; D014346:Trypanosoma brucei brucei / Q000187:drug effects / Q000378:metabolism; D014353:Trypanosomiasis, African / Q000188:drug therapy*
D065108:Ornithine Decarboxylase Inhibitors; D011073:Polyamines; D014344:Trypanocidal Agents; D009952:Ornithine; D000518:Eflornithine